Chronic Kidney Disease in Children (CKiD IV)

项目总结 儿童慢性肾脏疾病研究(CKiD)是一项多中心、前瞻性、观察性队列研究 在研究开始时，6个月至16岁的儿童肾功能轻度至中度受损。二 费城儿童医院(CHOP)的临床协调中心(CCCS)和儿童慈悲 医院和约翰霍普金斯大学彭博公共卫生学院的数据协调中心 形成了进行这项研究的合作协议。自2003年成立以来，CKiD的科学目标 已经确定了肾功能下降的危险因素和肾功能下降的影响 心血管疾病、生长障碍及其相关发病率、神经认知功能的危险因素 和行为。本申请的目的是申请从2018年8月起继续进行队列研究的资金 至2023年7月。目前提案的目标将在原来目标的基础上扩大，以包括完成 190例先天性肾、尿路及其他非肾小球畸形患儿的招募 慢性肾脏病病程早期的肾脏疾病，慢性肾脏病持续时间、透析和肾脏损害的影响特征 肾移植对心血管危险因素累积负担的远程体检评估 活动和血压，开发新的方法来确定CKD进展的危险因素， 通过与其他队列合作，加强儿童慢性肾脏病的研究，并继续提供 为科学界提供广泛的数据资源。中西部临床中心首席研究员 CMH协调中心在儿童肾脏疾病、临床研究设计、 招聘和保留、研究程序的质量控制以及跨部门协作的组织 CKiD的多个参与站点。CKiD的研究包括评估不同地理和种族的队列。 CKiD的结构及其对辅助研究的支持继续刺激新知识的产生 关于慢性肾脏病的进展以及相关共病的发展和演变 因为这些数据的公布。CKiD的基础设施继续作为职业生涯的平台 初级调查人员获得发展奖，较资深同事获得辅助R01奖。最重要的是， 随着更长时间的跟进和在CKD课程早期增加受试者，我们将继续 表征与慢性肾脏病进展及其后遗症相关的肾脏损害的新生物标志物以帮助 通知未来的治疗试验。

PROJECT SUMMARY The Chronic Kidney Disease in Children Study (CKiD) is a multi-center, prospective, observational cohort study of children aged 6 months to 16 years with mild to moderately impaired kidney function at study entry. Two clinical coordinating centers (CCCs) at the Children's Hospital of Philadelphia (CHOP), and Children's Mercy Hospital (CMH), and a data coordinating center at Johns Hopkins Bloomberg School of Public Health have formed a cooperative agreement to conduct this study. Since its inception in 2003, the scientific aims of CKiD have been to determine the risk factors for decline in kidney function and the effects of kidney function decline on the risk factors for cardiovascular disease, growth failure and its associated morbidity, neurocognitive function and behavior. The purpose of this application is to request funds to continue the cohort study from August, 2018 to July, 2023. The aims of the current proposal will expand on the original aims to include completion of recruitment of 190 children with congenital anomalies of the kidney and urinary tract and other non-glomerular kidney disorders early in the course of CKD, characterization of the impact of duration of CKD, dialysis and kidney transplantation on the cumulative burden of cardiovascular risk factors, remote assessment of physical activity and blood pressure, development of novel approaches to identify risk factors for CKD progression, enhancement of research in childhood CKD through collaboration with other cohorts, and continued provision of a broad data resource for the scientific community. The Principal Investigator of the Midwest Clinical Coordinating Center at CMH has clinical expertise in kidney disease in children, clinical research design, recruitment and retention, quality control of study procedures, and organization of collaboration across the multiple participating sites in CKiD. The CKiD study encompassess a geographically and racially diverse cohort. The structure of CKiD and its support of ancillary studies continues to stimulate the generation of new knowledge pertaining to the progression of CKD and the development and evolution of associated co-morbidities, as well as the publication of those data. The infrastructure of CKiD continues to serve as a platform for career development awards for junior investigators, and ancillary R01s for more senior colleagues. Most importantly, with longer follow-up and additional recruitment of subjects early in the course of CKD, we will contiune to characterize novel biomarkers of kidney inury that are associated with CKD progression and its sequellae to help inform future therapeutic trials.